.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,759,316

« Back to Dashboard

Claims for Patent: 8,759,316

Title:Maintenance of platelet inhibition during antiplatelet therapy
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Inventor(s): Ruderman Chen; Lisa (Rye, NY), Skerjanec; Simona (Basel, CH), Bell; Dawn (Morristown, NJ), Prats; Jayne (Carlisle, MA), Todd; Meredith (Hoboken, NJ), Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Mould; Diane (Fort Meyers, FL)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/931,384
Patent Claims: 1. A method of transitioning a patient in need thereof from administration of cangrelor during percutaneous coronary intervention (PCI) to administration of cangrelor in preparation for surgery, the method comprising: (1) administering a PCI dosing regimen, wherein the PCI dosing regimen comprises (i) administering intravenously a 30 .mu.g/kg bolus of cangrelor before the start of PCI; and (ii) administering intravenously a continuous infusion of cangrelor at an infusion rate of 4 .mu.g/kg/min after administration of the bolus; (2) discontinuing the administration of the PCI dosing regimen; and (3) administering a bridge dosing regimen, wherein the bridge dosing regimen comprises administering intravenously a continuous infusion of cangrelor at an infusion rate of 0.75 .mu.g/kg/min.

2. The method of claim 1, wherein the bolus is administered in less than one minute.

3. The method of claim 1, wherein the administration of the continuous infusion at the infusion rate of 4 .mu.g/kg/min is started immediately after the administration of the bolus.

4. The method of claim 1, wherein the cangrelor administered as the bolus is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

5. The method of claim 1, wherein the cangrelor administered as the continuous infusion at the infusion rate of 4 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

6. The method of claim 1, wherein the cangrelor administered as the continuous infusion at the infusion rate of 0.75 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

7. The method of claim 1, wherein the bridge dosing regimen is administered as quickly as possible following the discontinuation of the administration of the PCI dosing regimen.

8. The method of claim 1, wherein the discontinuation of the PCI dosing regimen and the administration of the bridge dosing regimen is achieved simultaneously by lowering the 4 .mu.g/kg/min infusion rate to the 0.75 .mu.g/kg/min infusion rate.

9. The method of claim 1, wherein the administration of the bridge dosing regimen is discontinued at least about one hour prior to administration of anesthesia for the surgery.

10. The method of claim 1, wherein administration of the bridge dosing regimen is discontinued after no longer than about 7 days from initiation of the bridge dosing regimen.

11. A method of transitioning a patient in need thereof from administration of cangrelor in preparation for surgery to administration of cangrelor during percutaneous coronary intervention (PCI), the method comprising: (1) administering a bridge dosing regimen, wherein the bridge dosing regimen comprises administering intravenously a continuous infusion of cangrelor at an infusion rate of 0.75 .mu.g/kg/min; (2) discontinuing the administration of the bridge dosing regimen; and (3) administering a PCI dosing regimen, wherein the PCI dosing regimen comprises (i) administering intravenously a 30 .mu.g/kg bolus of cangrelor before the start of PCI; and (ii) administering intravenously a continuous infusion of cangrelor at an infusion rate of 4 .mu.g/kg/min.

12. The method of claim 11, wherein the cangrelor administered as the continuous infusion at the infusion rate of 4 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

13. The method of claim 11, wherein the bolus is administered in less than one minute.

14. The method of claim 11, wherein the administration of the continuous infusion of cangrelor at the infusion rate of 4 .mu.g/kg/min is started immediately after the administration of the bolus.

15. The method of claim 11, wherein the discontinuation of the bridge dosing regimen and the administration of the PCI dosing regimen is achieved simultaneously by administering the bolus and increasing the 0.75 .mu.g/kg/min infusion rate to the 4 .mu.g/kg/min infusion rate.

16. The method of claim 11, wherein the cangrelor administered as the continuous infusion at the infusion rate of 0.75 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

17. The method of claim 11, wherein the cangrelor administered as the bolus is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

18. A method of transitioning a patient in need thereof from administration of cangrelor in preparation for surgery to administration of cangrelor during percutaneous coronary intervention (PCI), the method comprising: (1) administering a bridge dosing regimen, wherein the bridge dosing regimen comprises administering intravenously a continuous infusion of cangrelor at an infusion rate of 0.75 .mu.g/kg/min; (2) discontinuing the administration of the bridge dosing regimen; and (3) administering a PCI dosing regimen, wherein the PCI dosing regimen comprises administering intravenously a continuous infusion of cangrelor at an infusion rate of 4 .mu.g/kg/min during PCI.

19. The method of claim 18, wherein the discontinuation of the bridge dosing regimen and the administration of the PCI dosing regimen is achieved simultaneously by increasing the 0.75 .mu.g/kg/min infusion rate to the 4 .mu.g/kg/min infusion rate.

20. The method of claim 18, wherein the cangrelor administered as the continuous infusion at the infusion rate of 0.75 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

21. The method of claim 18, wherein the cangrelor administered as the continuous infusion at the infusion rate of 4 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

22. A method of transitioning a patient in need thereof from administration of cangrelor in preparation for surgery to administration of cangrelor during percutaneous coronary intervention (PCI), wherein the patient was being treated with a long-acting irreversible P2Y.sub.12 inhibitor that was discontinued prior to administration of cangrelor in preparation for surgery, the method comprising: (1) administering a bridge dosing regimen, wherein the bridge dosing regimen comprises administering intravenously a continuous infusion of cangrelor at an infusion rate of 0.75 .mu.g/kg/min; (2) discontinuing the administration of the bridge dosing regimen; and (3) administering a PCI dosing regimen, wherein the PCI dosing regimen comprises (i) administering intravenously a 30 .mu.g/kg bolus of cangrelor before the start of PCI; and (ii) administering intravenously a continuous infusion of cangrelor at an infusion rate of 4 .mu.g/kg/min.

23. The method of claim 22, wherein the cangrelor administered as the bolus is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

24. The method of claim 22, wherein the cangrelor administered as the continuous infusion at the infusion rate of 4 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.

25. The method of claim 22, wherein the bolus is administered in less than one minute.

26. The method of claim 22, wherein the administration of the continuous infusion of cangrelor at the infusion rate of 4 .mu.g/kg/min is started immediately after the administration of the bolus.

27. The method of claim 22, wherein the discontinuation of the bridge dosing regimen and the administration of the PCI dosing regimen is achieved simultaneously by administering the bolus and increasing the 0.75 .mu.g/kg/min infusion rate to the 4 .mu.g/kg/min infusion rate.

28. The method of claim 22, wherein the cangrelor administered as the continuous infusion at the infusion rate of 0.75 .mu.g/kg/min is in a pharmaceutical composition comprising 200 .mu.g/mL of cangrelor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc